FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Kenneth Mahaffey

Research Profile

Disorders

Concepts & Ideas

Procedures

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Jonathan Piccini; Daniel E Singer; Susanna R Stevens; Richard C Becker; Günter Breithardt; Robert M Califf; Keith A A Fox; Werner Hacke; Jonathan L Halperin; Graeme J Hankey; Yuliya Lokhnygina; Kenneth W Mahaffey; Christopher C. Nessel; Manesh R Patel
Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial.
Sumeet Subherwal; Tracy Y Wang; John H Alexander; Karen P Alexander; Vic Hasselblad; Kenneth W Mahaffey; E Magnus Ohman; Sunil V Rao; Matthew T Roe
Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: Validity, pitfalls, and future approaches.
Jason J Rose; Frans Van de Werf; Harvey D White; Kenneth W Mahaffey; L Kristin Newby; E Magnus Ohman; Paul W Armstrong; Samuel Broderick; Robert M Califf; Karen Chiswell; Robert P Giugliano; Shaun G Goodman; Christopher B Granger; Robert A Harrington; Renato D Lopes
Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Kenneth Mahaffey (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jonathan Piccini; Daniel E Singer; Susanna R Stevens; Richard C Becker; Günter Breithardt; Robert M Califf; Keith A A Fox; Werner Hacke; Jonathan L Halperin; Graeme J Hankey; Yuliya Lokhnygina; Kenneth W Mahaffey; Christopher C. Nessel; Manesh R Patel
Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial.
Journal of the American College of Cardiology 2013;61(19):1998-2006.
2013: Sumeet Subherwal; Tracy Y Wang; John H Alexander; Karen P Alexander; Vic Hasselblad; Kenneth W Mahaffey; E Magnus Ohman; Sunil V Rao; Matthew T Roe
Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: Validity, pitfalls, and future approaches.
American heart journal 2013;165(5):644-654.e1.
2013: Jason J Rose; Frans Van de Werf; Harvey D White; Kenneth W Mahaffey; L Kristin Newby; E Magnus Ohman; Paul W Armstrong; Samuel Broderick; Robert M Califf; Karen Chiswell; Robert P Giugliano; Shaun G Goodman; Christopher B Granger; Robert A Harrington; Renato D Lopes
Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes.
Journal of the American College of Cardiology 2013;61(13):1461-3.
2013: Benjamin A Steinberg; James Reiffel; Paul Chang; Michael D Ezekowitz; Gregg C Fonarow; DaJuanicia N Holmes; Peter R Kowey; Kenneth W Mahaffey; Gerald Naccarelli; Eric D Peterson; Jonathan P Piccini
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
American heart journal 2013;165(4):622-9.
2013: Cynthia M Westerhout; Robert M Califf; Frans Van de Werf; Christopher B Granger; Stefan K James; Kenneth W Mahaffey; Karen S Pieper; Paul W Armstrong
Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
American heart journal 2013;165(3):354-62.e2.
2013: Manesh R Patel; Jonathan Piccini; Daniel E Singer; Zhongxin Zhang; Surya Mohanty; Christopher C. Nessel; Richard C Becker; Scott D Berkowitz; Günter Breithardt; Robert M Califf; Keith A A Fox; Werner Hacke; Jonathan L Halperin; Graeme J Hankey; Anne S Hellkamp; Yuliya Lokhnygina; Kenneth W Mahaffey
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Journal of the American College of Cardiology 2013;61(6):651-8.
2013: Jonathan Piccini; Daniel E Singer; Susanna R Stevens; Richard C Becker; Günter Breithardt; Robert M Califf; Yuchiao Chang; Keith A A Fox; Alan S Go; Werner Hacke; Jonathan L Halperin; Graeme J Hankey; Yuliya Lokhnygina; Kenneth W Mahaffey; Christopher C. Nessel; Manesh R Patel
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Circulation 2013;127(2):224-32.
2012: Sergio Leonardi; Renato D Lopes; Elliott M Antman; Paul W Armstrong; Robert M Califf; Robert P Giugliano; Megan L Neely; L Kristin Newby; Laine Thomas; Pierluigi Tricoci; Harvey D White; Kenneth W Mahaffey
Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction.
Journal of the American College of Cardiology 2012;60(22):2296-304.
2012: Connie N Hess; John H Alexander; Karen P Alexander; Samuel Broderick; Christopher B Granger; Kenneth W Mahaffey; L Kristin Newby; Eric D Peterson; Jonathan P Piccini; Linda K Shaw; Renato D Lopes
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients.
American heart journal 2012;164(4):607-15.
2012: Zubin J Eapen; G Michael Felker; Adrian F Hernandez; A Michael Lincoff; Kenneth W Mahaffey; W H Wilson Tang; Matthew T Roe
Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward.
Circulation. Cardiovascular quality and outcomes 2012;5(4):594-600.
2012: Michael P Thomas; Elliott M Antman; Robert M Califf; Karen Chiswell; Marc Cohen; James J Ferguson; Shaun G Goodman; Michael C Kontos; Kenneth W Mahaffey; Richard C Becker
Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin.
Journal of thrombosis and thrombolysis 2012;34(1):114-9.
2012: Sean van Diepen; Paul W Armstrong; Justin A Ezekowitz; Christian W Hamm; Judith S Hochman; Stefan James; Renato D Lopes; Kenneth W Mahaffey; David J Moliterno; Franz-Josef Neumann; L Kristin Newby; Matthew T Roe; Amanda L Stebbins; Pierre Theroux; Christopher B Granger
Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial.
Journal of thrombosis and thrombolysis 2012;34(1):106-13.
2012: James S Mills; Jose C Nicolau; Witold Ruzyllo; Thomas G Todaro; Peter X Adams; Paul W Armstrong; Christopher B Granger; Yuliya Lokhnygina; Kenneth W Mahaffey
Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction.
Coronary artery disease 2012;23(2):118-25.
2012: Harvey D White; Derek P Chew; Harold L Dauerman; C Michael Gibson; Luis Gruberg; Robert A Harrington; Kenneth W Mahaffey; Gregg W Stone; Deepak L Bhatt
Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction.
American heart journal 2012;163(2):182-90.e4.
2011: Jonathan P Piccini; Laine E Thomas; Jack E Ansell; Gregg C Fonarow; Elizabeth S Fraulo; Bernard J Gersh; Alan S Go; Elaine M Hylek; Melissa H Kong; Peter R Kowey; Renato D Lopes; Kenneth W Mahaffey; Roger M Mills; Eric D Peterson
Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF.
American heart journal 2011;162(4):606-612.e1.
2011: Keith A A Fox; Jonathan L Halperin; Graeme J Hankey; Kenneth W Mahaffey; Christopher C. Nessel; John F Paolini; Manesh R Patel; Jonathan P Piccini; Daniel E Singer; Daniel Wojdyla; Richard C Becker; Robert M Califf
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
European heart journal 2011;32(19):2387-94.
2011: Manesh R Patel; Jonathan P Piccini; Daniel E Singer; Richard C Becker; Scott Darrell Berkowitz; Günter Breithardt; Robert M Califf; Keith A A Fox; Jyotsna Garg; Werner Hacke; Jonathan L Halperin; Graeme J Hankey; Kenneth W Mahaffey; Christopher C. Nessel; Guohua Pan; John F Paolini
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
The New England journal of medicine 2011;365(10):883-91.
2011: Kenneth W Mahaffey; Karen S Pieper; Robert F Storey; Lars Wallentin; Daniel M Wojdyla; Dominick J Angiolillo; Richard C Becker; Christopher P Cannon; Kevin Carroll; Robert A Harrington; Claes Held; Jay Horrow; Stefan James
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Circulation 2011;124(5):544-54.
2011: Renato D Lopes; Kenneth W Mahaffey; Helena B Nader; L Kristin Newby; Eric D Peterson; Karen S Pieper; Frans Van de Werf; Lars Wallentin; Harvey D White; John H Alexander; Paul W Armstrong; Richard C Becker; Joyce M A Bizzachi; Robert M Califf; Antonio C Carvalho; Mark Y Chan; Mark Crowther; Roberto R Giraldez; Christopher B Granger; Helio P Guimaraes; Robert A Harrington; Elaine M Hylek; Stefan K James; E Marc Jolicoeur; Renato A K Kalil; Antonio C Lopes; David A Garcia
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil.
Journal of thrombosis and thrombolysis 2011;32(2):242-66.
2011: Kenneth W Mahaffey; Karen S Pieper; Yuliya Lokhnygina; Robert M Califf; Elliott M Antman; Neal S Kleiman; Shaun G Goodman; Harvey D White; Sunil V Rao; Judith S Hochman; Marc Cohen; Jacques J Col; Matthew T Roe; James J Ferguson
The impact of postrandomization crossover of therapy in acute coronary syndromes care.
Circulation. Cardiovascular quality and outcomes 2011;4(2):211-9.
2011: Kenneth W Mahaffey; June L Wampole; Amanda Stebbins; Lisa G Berdan; Donna McAfee; Tyrus L Rorick; John K French; Neal S Kleiman; Christopher M O'Connor; Eric A Cohen; Christopher B Granger; Paul W Armstrong
Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
Contemporary clinical trials 2011;32(2):178-87.
2011: Richard C Becker; Kenneth W Mahaffey; Hongqiu Yang; A J Marian; Mark I Furman; A Michael Lincoff; Stanley L Hazen; John L Petersen; Craig J Reist; Neal S Kleiman
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome.
Journal of thrombosis and thrombolysis 2011;31(2):146-53.
2010: Jonathan P Piccini; Renato D Lopes; Kenneth W Mahaffey
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Current opinion in cardiology 2010;25(4):312-20.
2010: Kenneth W Mahaffey; Simon T Tonev; Sarah A Spinler; Glenn N Levine; Richard Gallo; John Ducas; Shaun G Goodman; Elliott M Antman; Richard C Becker; Anatoly Langer; Harvey D White; Philip E Aylward; Jacques J Col; James J Ferguson; Robert M Califf
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
International journal of cardiology 2010;139(2):123-33.
2010: Bimal R Shah; Eric D Peterson; Anita Y Chen; Kenneth W Mahaffey; Elizabeth R DeLong; E Magnus Ohman; Charles V Pollack; W Brian Gibler; Matthew T Roe
Influence of clinical trial participation on subsequent antithrombin use.
Clinical cardiology 2010;33(3):E49-55.
2010: Michael C Tjandrawidjaja; Yuling Fu; Cynthia M Westerhout; Harvey D White; Thomas G Todaro; Frans Van de Werf; Kenneth W Mahaffey; Galen S Wagner; Christopher B Granger; Paul W Armstrong
Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction.
European heart journal 2010;31(5):573-81.
2010: Renato D Lopes; Aijing Starr; Carl F Pieper; Sana M Al-Khatib; L Kristin Newby; Rajendra H Mehta; Frans Van de Werf; Kenneth W Mahaffey; Paul W Armstrong; Robert A Harrington; Harvey D White; Lars Wallentin; Christopher B Granger
Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes.
The American journal of medicine 2010;123(2):134-40.
2009: Robert A Harrington; Gregg W Stone; Steven McNulty; Harvey D White; A Michael Lincoff; C Michael Gibson; Charles V Pollack; Gilles Montalescot; Kenneth W Mahaffey; Neal S Kleiman; Shaun G Goodman; Maged Amine; Dominick J Angiolillo; Richard C Becker; Derek P Chew; William J French; Franz Leisch; Keyur H Parikh; Simona Skerjanec; Deepak L Bhatt
Platelet inhibition with cangrelor in patients undergoing PCI.
The New England journal of medicine 2009;361(24):2318-29.
2009: Jason P Linefsky; Min Lin; Karen S Pieper; Craig J Reist; Lisa G Berdan; Elliott M Antman; Shaun G Goodman; John K French; Sema Guneri; Matthew T Roe; L Kristin Newby; Robert A Harrington; James J Ferguson; Robert M Califf; Kenneth W Mahaffey
Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY).
The American journal of cardiology 2009;104(10):1330-5.
2009: Aslan T Turer; Kenneth W Mahaffey; Emily Honeycutt; Robert H Tuttle; Linda K Shaw; Michael H Sketch; Peter K Smith; Robert M Califf; John H Alexander
Influence of body mass index on the efficacy of revascularization in patients with coronary artery disease.
The Journal of thoracic and cardiovascular surgery 2009;137(6):1468-74.
2009: Paul W Armstrong; Yuling Fu; Cynthia M Westerhout; Michael P Hudson; Kenneth W Mahaffey; Harvey D White; Thomas G Todaro; Peter X Adams; Philip E G Aylward; Christopher B Granger
Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention.
Journal of the American College of Cardiology 2009;53(17):1503-9.
2009: Richard C Becker; David J Moliterno; Lisa K Jennings; Karen S Pieper; Jinglan Pei; Alan Niederman; Khaled M Ziada; Gail Berman; John Strony; Diane Joseph; Kenneth W Mahaffey; Frans Van de Werf; Enrico Veltri; Robert A Harrington
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.
Lancet 2009;373(9667):919-28.
2008: Kenneth W Mahaffey; Craig J Reist; Yuling Fu; Sorin J Brener; Pierre Theroux; Manesh R Patel; Amanda Stebbins; Cynthia M Westerhout; Thomas G Todaro; Peter X Adams; Christopher B Granger; Paul W Armstrong
Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library.
Contemporary clinical trials 2008;29(6):887-95.
2008: Christopher E Buller; Yuling Fu; Kenneth W Mahaffey; Thomas G Todaro; Peter Adams; Cynthia M Westerhout; Harvey D White; Arnoud W J van 't Hof; Frans J Van de Werf; Galen S Wagner; Christopher B Granger; Paul W Armstrong
ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
Circulation 2008;118(13):1335-46.
2008: James M Yau; John H Alexander; Gail E Hafley; Kenneth W Mahaffey; Michael J Mack; Nicholas T Kouchoukos; Abhinav Goyal; eric peterson; C Michael Gibson; Robert M Califf; Robert A Harrington; T. Bruce Ferguson
Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV).
The American journal of cardiology 2008;102(5):546-51.
2008: Mark Y Chan; Kenneth W Mahaffey; Lena J Sun; Karen S Pieper; Harvey D White; Philip E Aylward; James J Ferguson; Robert M Califf; Matthew T Roe
Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease.
JACC. Cardiovascular interventions 2008;1(4):369-78.
2008: Chadwick D Miller; G J Fermann; Christopher J Lindsell; Kenneth W Mahaffey; W Frank Peacock; Charles V Pollack; Judd E Hollander; Deborah B Diercks; W Brian Gibler; J W Hoekstra
Initial risk stratification and presenting characteristics of patients with evolving myocardial infarctions.
Emergency medicine journal : EMJ 2008;25(8):492-7.
2008: Chiara Melloni; Kenneth W Mahaffey
Management of acute coronary syndromes in patients with renal dysfunction.
Current opinion in cardiology 2008;23(4):320-6.
2008: Jonathan P Piccini; Manesh R Patel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf
Rivaroxaban, an oral direct factor Xa inhibitor.
Expert opinion on investigational drugs 2008;17(6):925-37.
2008: Kenneth W Mahaffey; Qinghong Yang; Karen S Pieper; Elliott M Antman; Harvey D White; Shaun G Goodman; Marc Cohen; Neal S Kleiman; Anatoly Langer; Philip E G Aylward; Jacques J Col; Craig J Reist; James J Ferguson; Robert M Califf
Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial.
Journal of general internal medicine 2008;23(3):310-6.
2007: Pierluigi Tricoci; Yuliya Lokhnygina; Lisa G Berdan; Steven R Steinhubl; Dietrich C Gulba; Harvey D White; Neal S Kleiman; Philip E G Aylward; Anatoly Langer; Robert M Califf; James J Ferguson; Elliott M Antman; L Kristin Newby; Robert A Harrington; Shaun G Goodman; Kenneth W Mahaffey
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
Circulation 2007;116(23):2669-77.
2007: Chadwick D Miller; Anindita Banerjee; Kenneth W Mahaffey; Michael C Kontos; Gregory Fermann; Charles V Pollack; Elliott M Antman; Philip E G Aylward; Shaun G Goodman; Renato Santos; James J Ferguson; Robert M Califf; James W Hoekstra
Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial.
European heart journal 2007;28(9):1079-84.
2007: Aslan T Turer; Kenneth W Mahaffey; Kate L Compton; Robert M Califf; Kevin Schulman
Publication or presentation of results from multicenter clinical trials: evidence from an academic medical center.
American heart journal 2007;153(4):674-80.
2007: Kenneth W Mahaffey; Matthew T Roe; Rakhi Kilaru; John H Alexander; Frans Van de Werf; Robert M Califf; Maarten L Simoons; Eric J Topol; Robert A Harrington
Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials.
European heart journal 2007;28(4):425-32.
2007: Melvin R Echols; Kenneth W Mahaffey; Anindita Banerjee; Karen S Pieper; Amanda L Stebbins; Alexandra Lansky; Mauricio G. Cohen; Eric Velazquez; Renato Santos; L Kristin Newby; Enrique P Gurfinkel; Luigi Biasucci; James J Ferguson; Robert M Califf
Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial).
The American journal of cardiology 2007;99(3):315-21.
2007: Warren J Cantor; Kenneth W Mahaffey; Zhen Huang; Pranab Das; Dietrich C Gulba; Stanislav Glezer; Richard Gallo; John Ducas; Marc Cohen; Elliott M Antman; Anatoly Langer; Neal S Kleiman; Harvey D White; Robert J Chisholm; Robert A Harrington; James J Ferguson; Robert M Califf; Shaun G Goodman
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2007;69(1):73-83.
2006: Harvey D White; Neal S Kleiman; Kenneth W Mahaffey; Yuliya Lokhnygina; Karen S Pieper; Karen Chiswell; Marc Cohen; Robert A Harrington; Derek P Chew; John L Petersen; Lisa G Berdan; Philip E G Aylward; Christopher C. Nessel; James J Ferguson; Robert M Califf
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
American heart journal 2006;152(6):1042-50.
2006: Kenneth W Mahaffey; Frans Van de Werf; Stanton K Shernan; Christopher B Granger; Edward D Verrier; Thomas G Filloon; Thomas G Todaro; Peter X Adams; Jerrold H Levy; Vic Hasselblad; Paul W Armstrong
Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview.
American heart journal 2006;152(2):291-6.
2006: Glen L Xiong; Wei Jiang; Robert Clare; Linda K Shaw; Peter K Smith; Kenneth W Mahaffey; Christopher M O'Connor; K Ranga Rama Krishnan; L Kristin Newby
Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting.
The American journal of cardiology 2006;98(1):42-7.
2006: Kanwar P Singh; Matthew T Roe; eric peterson; Anita Y Chen; Kenneth W Mahaffey; Shaun G Goodman; Robert A Harrington; Sidney C Smith; W Brian Gibler; Erik Ohman; Charles V Pollack
Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative.
Journal of thrombosis and thrombolysis 2006;21(3):211-20.
2006: Cheryl D Bushnell; Jeffrey Griffin; L Kristin Newby; Larry B Goldstein; Kenneth W Mahaffey; Carmelo Graffagnino; Robert A Harrington; Harvey D White; R John Simes; Robert M Califf; Eric J Topol; J Donald Easton
Statin use and sex-specific stroke outcomes in patients with vascular disease.
Stroke; a journal of cerebral circulation 2006;37(6):1427-31.
2006: Abhinav Goyal; Kenneth W Mahaffey; Jyotsna Garg; Jose C Nicolau; Judith S Hochman; W Douglas Weaver; Pierre Theroux; Gustavo B F Oliveira; Thomas G Todaro; Christopher F Mojcik; Paul W Armstrong; Christopher B Granger
Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study.
European heart journal 2006;27(11):1289-97.
2006: John L Petersen; Ghazala Haque; Anne S Hellkamp; Greg C Flaker; N A Mark Estes; Francis E Marchlinski; John H McAnulty; Arnold J Greenspon; Roger A Marinchak; Kerry L Lee; Gervasio A Lamas; Kenneth W Mahaffey
Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee.
Contemporary clinical trials 2006;27(3):260-8.
2006: Justin A Ezekowitz; Pierre Théroux; Weiching Chang; Kenneth W Mahaffey; Christopher B Granger; W Douglas Weaver; Judith S Hochman; Paul W Armstrong
N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction.
The Canadian journal of cardiology 2006;22(5):393-7.
2006: Paul W Armstrong; Kenneth W Mahaffey; Wei-Ching Chang; W Douglas Weaver; Judith S Hochman; Pierre Theroux; Scott A Rollins; Thomas G Todaro; Christopher B Granger
Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction.
American heart journal 2006;151(4):787-90.
2006: Sunil V Rao; Kristi O'Grady; Karen S Pieper; Christopher B Granger; L Kristin Newby; Kenneth W Mahaffey; David J Moliterno; A Michael Lincoff; Paul W Armstrong; Frans Van de Werf; Robert M Califf; Robert A Harrington
A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes.
Journal of the American College of Cardiology 2006;47(4):809-16.
2006: Wei-Ching Chang; Padma Kaul; Yuling Fu; Cynthia M Westerhout; Christopher B Granger; Kenneth W Mahaffey; Lars Wallentin; Frans Van de Werf; Paul W Armstrong
Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction.
European heart journal 2006;27(4):419-26.
2006: Kenneth W Mahaffey
Acute coronary syndromes: what have we learned about what we still need to know?
Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital 2006;33(2):187-9.
2006: John M Galla; Kenneth W Mahaffey; Shelly K Sapp; John H Alexander; Matthew T Roe; Erik Ohman; Christopher B Granger; Paul W Armstrong; Robert A Harrington; Harvey D White; Maarten L Simoons; L Kristin Newby; Robert M Califf; Eric J Topol
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials.
American heart journal 2006;151(1):16-24.
2005: Kenneth W Mahaffey; Marc Cohen; Jyotsna Garg; Elliott M Antman; Neal S Kleiman; Shaun G Goodman; Lisa G Berdan; Craig J Reist; Anatoly Langer; Harvey D White; Philip E G Aylward; Jacques J Col; James J Ferguson; Robert M Califf
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.
JAMA : the journal of the American Medical Association 2005;294(20):2594-600.
2005: Sunil V Rao; Kristi O'Grady; Karen S Pieper; Christopher B Granger; L Kristin Newby; Frans Van de Werf; Kenneth W Mahaffey; Robert M Califf; Robert A Harrington
Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes.
The American journal of cardiology 2005;96(9):1200-6.
2005: Alejandro Barbagelata; Marcelo F Di Carli; Robert M Califf; Jyotsna Garg; Yochai Birnbaum; Liliana Grinfeld; Raymond J Gibbons; Christopher B Granger; Shaun G Goodman; Galen S Wagner; Kenneth W Mahaffey
Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial.
American heart journal 2005;150(4):659-65.
2005: Glenn N Levine; A Michael Lincoff; James J Ferguson; Kenneth W Mahaffey; Shaun G Goodman; Christopher P Cannon; Pierre Theroux; Keith A A Fox
Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2005;66(2):149-57.
2005: Karolina E Szummer; Scott D Solomon; Eric J Velazquez; Rakhi Kilaru; John McMurray; Jean-Lucien Rouleau; Kenneth W Mahaffey; Aldo P Maggioni; Robert M Califf; Marc A Pfeffer; Harvey D White
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry.
European heart journal 2005;26(20):2114-9.
2005: Pierre Théroux; Paul W Armstrong; Kenneth W Mahaffey; Judith S Hochman; Kevin J Malloy; Scott A Rollins; Jose C Nicolau; Joel Lavoie; The Minh Luong; Jeb Burchenal; Christopher B Granger
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.
European heart journal 2005;26(19):1964-70.
2005: Aslan T Turer; Kenneth W Mahaffey; Dianne Gallup; W Douglas Weaver; Robert H Christenson; Nathan R Every; Erik Ohman
Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction.
Current controlled trials in cardiovascular medicine 2005;6():12.
2005: Kenneth W Mahaffey; Matthew T Roe; Rakhi Kilaru; John K French; John H Alexander; Lisa G Berdan; Frans Van de Werf; Maarten L Simoons; W Douglas Weaver; Harvey D White; A Michael Lincoff; Neal S Kleiman; Eric J Topol; Robert A Harrington
Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes.
The American journal of cardiology 2005;95(12):1404-8.
2005: John M Galla; Kenneth W Mahaffey
Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes.
Expert opinion on pharmacotherapy 2005;6(7):1241-51.
2005: Robert M Califf; John L Petersen; Vic Hasselblad; Kenneth W Mahaffey; James J Ferguson
A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
American heart journal 2005;149(4 Suppl):S91-9.
2005: Kenneth W Mahaffey; James J Ferguson
Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
American heart journal 2005;149(4 Suppl):S81-90.
2005: Manesh R Patel; Kenneth W Mahaffey; Paul W Armstrong; W Douglas Weaver; Gudaye Tasissa; Judith S Hochman; Thomas G Todaro; Kevin J Malloy; Scott A Rollins; Pierre Theroux; Witold Ruzyllo; Jose C Nicolau; Christopher B Granger
Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial).
The American journal of cardiology 2005;95(5):614-8.
2005: Brett D Atwater; Matthew T Roe; Kenneth W Mahaffey
Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection.
Drugs 2005;65(3):313-24.
2004: Hassan Kassem-Moussa; Kenneth W Mahaffey; Carmelo Graffagnino; Gudaye Tasissa; Cathy A Sila; R John Simes; Harvey D White; Robert M Califf; Manjushri Bhapkar; L Kristin Newby
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome.
American heart journal 2004;148(3):439-46.
2004: John L Petersen; Kenneth W Mahaffey; Richard C Becker; Shaun G Goodman; Neal S Kleiman; A J Marian; Gregg W Stone; Alexandra J Lansky; A Michael Lincoff; Stanley L Hazen; Christopher C. Nessel; Luis Toro-Figueroa; Lynn Tate; Craig J Reist; Marc Cohen; Robert M Califf; James J Ferguson
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
American heart journal 2004;148(2):269-76.
2004: John L Petersen; Kenneth W Mahaffey; Vic Hasselblad; Elliott M Antman; Marc Cohen; Shaun G Goodman; Anatoly Langer; Michael A Blazing; Anne Le-Moigne-Amrani; James A de Lemos; Christopher C. Nessel; Robert A Harrington; James J Ferguson; Eugene Braunwald; Robert M Califf
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
JAMA : the journal of the American Medical Association 2004;292(1):89-96.
2004: Abhinav Goyal; John L Petersen; Kenneth W Mahaffey
The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes.
Current cardiology reports 2004;6(4):300-7.
2004: Richard E Waters; Kanwar P Singh; Matthew T Roe; Mat Lotfi; Michael H Sketch; Kenneth W Mahaffey; L Kristin Newby; John H Alexander; Robert A Harrington; Robert M Califf; Christopher B Granger
Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Journal of the American College of Cardiology 2004;43(12):2153-9.
2004: David E Kandzari; Christopher B Granger; Maarten L Simoons; Harvey D White; R John Simes; Kenneth W Mahaffey; Joel Gore; W Douglas Weaver; William T Longstreth; Amanda L Stebbins; Kerry L Lee; Robert M Califf; Eric J Topol
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).
The American journal of cardiology 2004;93(4):458-61.
2004: Matthew T Roe; Kenneth W Mahaffey; Rakhi Kilaru; John H Alexander; K Martijn Akkerhuis; Maarten L Simoons; Robert A Harrington; Barbara E Tardiff; Christopher B Granger; Erik Ohman; David J Moliterno; A Michael Lincoff; Paul W Armstrong; Frans Van de Werf; Robert M Califf; Eric J Topol
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes.
European heart journal 2004;25(4):313-21.
2004: Abdallah G Rebeiz; Matthew T Roe; John H Alexander; Kenneth W Mahaffey; Christopher B Granger; eric peterson; Robert M Califf; Robert A Harrington
Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes.
The American journal of medicine 2004;116(2):119-29.
2003: Richard E Waters; Kenneth W Mahaffey; Christopher B Granger; Matthew T Roe
Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies.
American heart journal 2003;146(6):958-68.
2003: John H Alexander; Robert A Harrington; Manjushri Bhapkar; Kenneth W Mahaffey; A Michael Lincoff; Erik Ohman; Peter Klootwijk; Olle Pahlm; Bo Henden; Jaap Deckers; Maarten L Simoons; Robert M Califf; Galen S Wagner
Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes.
The American journal of medicine 2003;115(8):613-9.
2003: Kenneth W Mahaffey; Bruce E Lewis; Nancy M Wildermann; Scott Darrell Berkowitz; Renee M Oliverio; Mark Turco; Yoseph Shalev; Peter Ver Lee; Jay H Traverse; A Ralph Rodriguez; Erik Ohman; Robert A Harrington; Robert M Califf
The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results.
The Journal of invasive cardiology 2003;15(11):611-6.
2003: Kenneth W Mahaffey; Christopher B Granger; Jose C Nicolau; Witold Ruzyllo; W Douglas Weaver; Pierre Theroux; Judith S Hochman; Thomas G Filloon; Christopher F Mojcik; Thomas G Todaro; Paul W Armstrong
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.
Circulation 2003;108(10):1176-83.
2003: Christopher B Granger; Kenneth W Mahaffey; W Douglas Weaver; Pierre Theroux; Judith S Hochman; Thomas G Filloon; Scott A Rollins; Thomas G Todaro; Jose C Nicolau; Witold Ruzyllo; Paul W Armstrong
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
Circulation 2003;108(10):1184-90.
2003: A Hersi; Yuling Fu; B Wong; Kenneth W Mahaffey; Robert A Harrington; Robert M Califf; Frans Van de Werf; Paul W Armstrong
Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission?
European heart journal 2003;24(6):522-31.
2003: Padma Kaul; L Kristin Newby; Yuling Fu; Vic Hasselblad; Kenneth W Mahaffey; Robert H Christenson; Robert A Harrington; Erik Ohman; Eric J Topol; Robert M Califf; Frans Van de Werf; Paul W Armstrong
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients.
Journal of the American College of Cardiology 2003;41(3):371-80.
2002: Debabrata Mukherjee; Kenneth W Mahaffey; David J Moliterno; Robert A Harrington; Jay S Yadav; Karen S Pieper; Dianne Gallup; Christopher Dyke; Matthew T Roe; Lisa G Berdan; Michael Lauer; Matti Mänttäri; Harvey D White; Robert M Califf; Eric J Topol
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
American heart journal 2002;144(6):995-1002.
2002: Peter B Berger; Kenneth W Mahaffey; Susan J Meier; Christopher E Buller; Wayne Batchelor; Edward T A Fry; James P Zidar
Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial.
American heart journal 2002;143(5):841-6.
2002: David E Kandzari; Kenneth W Mahaffey
Experience with glycoprotein IIb/IIIa antagonists in patients with acute coronary syndromes.
Journal of interventional cardiology 2002;15(2):121-9.
2002: Kenneth W Mahaffey; Matthew T Roe; Christopher K Dyke; L Kristin Newby; Neal S Kleiman; Patty Connolly; Lisa G Berdan; rodney sparapani; Kerry L Lee; Paul W Armstrong; Eric J Topol; Robert M Califf; Robert A Harrington
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial.
American heart journal 2002;143(2):242-8.
2002: Yochai Birnbaum; Kenneth W Mahaffey; Douglas A Criger; Kathy B Gates; Gabriel I Barbash; Alejandro Barbagelata; Peter Clemmensen; Elena B Sgarbossa; Raymond J Gibbons; M Atiar Rahman; Robert M Califf; Chistopher B Granger; Galen S Wagner
Grade III ischemia on presentation with acute myocardial infarction predicts rapid progression of necrosis and less myocardial salvage with thrombolysis.
Cardiology 2002;97(3):166-74.
2001: Wayne Batchelor; Kenneth W Mahaffey; Peter B Berger; E Deutsch; S Meier; Vic Hasselblad; Edward T A Fry; P S Teirstein; A M Ross; Cynthia Binanay; James P Zidar
A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial.
Journal of the American College of Cardiology 2001;38(6):1608-13.
2001: Kenneth W Mahaffey
Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
Current cardiology reports 2001;3(5):362-70.
2001: Sana M Al-Khatib; Karen S Pieper; K L Lee; Kenneth W Mahaffey; Judith S Hochman; C J Pepine; S L Kopecky; M Akkerhuis; J Stepinska; Maarten L Simoons; Eric J Topol; Robert M Califf; Robert A Harrington
Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial.
The American journal of cardiology 2001;88(1):A7, 76-9.
2001: Matthew T Roe; Erik Ohman; Arthur C P Maas; Robert H Christenson; Kenneth W Mahaffey; Christopher B Granger; Robert A Harrington; Robert M Califf; Mitchell W Krucoff
Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion.
Journal of the American College of Cardiology 2001;37(1):9-18.
2000: K R Campbell; Kenneth W Mahaffey; Bruce E Lewis; J I Weitz; Scott Darrell Berkowitz; Erik Ohman; Robert M Califf
Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.
The Journal of invasive cardiology 2000;12 Suppl F():14F-9.
2000: K Martijn Akkerhuis; Jaap Deckers; eric boersma; Robert A Harrington; J Stepinska; Kenneth W Mahaffey; Robert G Wilcox; A Michael Lincoff; Mátyás Keltai; Eric J Topol; Robert M Califf; Maarten L Simoons
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT.
European heart journal 2000;21(5):371-81.
2000: Daniel B Mark; Robert A Harrington; A Michael Lincoff; Robert M Califf; Charlotte L Nelson; Anastasios A Tsiatis; Hope E Buell; Kenneth W Mahaffey; Linda Davidson-Ray; Eric J Topol
Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes.
Circulation 2000;101(4):366-71.
2000: John H Alexander; rodney sparapani; Kenneth W Mahaffey; Jaap Deckers; L Kristin Newby; Erik Ohman; R Corbalán; S L Chierchia; J B Boland; Maarten L Simoons; Robert M Califf; Eric J Topol; Robert A Harrington
Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
JAMA : the journal of the American Medical Association 2000;283(3):347-53.
1999: Kenneth W Mahaffey; JA Puma; N A Barbagelata; M F DiCarli; M A Leesar; K F Browne; P R Eisenberg; Roberto Bolli; A C Casas; V Molina-Viamonte; C Orlandi; R Blevins; Raymond J Gibbons; Robert M Califf; Christopher B Granger
Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial.
Journal of the American College of Cardiology 1999;34(6):1711-20.
1999: Kenneth W Mahaffey; Christopher B Granger; Michael A Sloan; Cynthia L Green; Joel M Gore; W Douglas Weaver; Harvey D White; Maarten L Simoons; Gabriel I Barbash; Eric J Topol; Robert M Califf
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries.
American heart journal 1999;138(3 Pt 1):493-9.
1999: Kenneth W Mahaffey; Robert A Harrington; Maarten L Simoons; Christopher B Granger; Carmelo Graffagnino; Mark J Alberts; Daniel T Laskowitz; Julie M Miller; Michael A Sloan; Lisa G Berdan; C M MacAulay; A Michael Lincoff; Jaap Deckers; Eric J Topol; Robert M Califf
Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
Circulation 1999;99(18):2371-7.
1999: C Y Tung; Christopher B Granger; Michael A Sloan; Eric J Topol; J D Knight; W Douglas Weaver; Kenneth W Mahaffey; H White; Nancy E Clapp-Channing; Maarten L Simoons; J M Gore; Robert M Califf; Daniel B Mark
Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study.
Circulation 1999;99(3):370-6.
1999: Alejandro Barbagelata; Marcelo F Di Carli; Elena B Sgarbossa; Robert M Califf; Peter Clemmensen; Douglas A Criger; Kathy B Gates; R J Gibbons; H Casabe; Christopher B Granger; Galen S Wagner; Kenneth W Mahaffey
The use of tomographic myocardial perfusion scanning to evaluate an electrocardiographic salvage estimation method in patients with acute myocardial infarction: an AMISTAD substudy. Acute Myocardial Infarction Study Adenosine.
Journal of electrocardiology 1999;32 Suppl():111-3.
1999: Barbara E Tardiff; Robert M Califf; James E Tcheng; A Michael Lincoff; Kristina N Sigmon; Robert A Harrington; Kenneth W Mahaffey; Erik Ohman; P S Teirstein; James C Blankenship; Michael M Kitt; Eric J Topol
Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II.
Journal of the American College of Cardiology 1999;33(1):88-96.
1998: Michael A Sloan; Cathy A Sila; Kenneth W Mahaffey; Christopher B Granger; W T Longstreth; Peter J Koudstaal; Harvey D White; Joel M Gore; Maarten L Simoons; W Douglas Weaver; Cynthia L Green; Eric J Topol; Robert M Califf
Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage.
Circulation 1998;98(14):1376-82.
1998: James Gebel; Cathy A Sila; Michael A Sloan; Christopher B Granger; J P Weisenberger; Cynthia L Green; Eric J Topol; Kenneth W Mahaffey
Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial.
Stroke; a journal of cerebral circulation 1998;29(9):1799-801.
1998: Kenneth W Mahaffey; Christopher B Granger; Michael A Sloan; TD Thompson; Joel M Gore; W Douglas Weaver; Harvey D White; Maarten L Simoons; Gabriel I Barbash; Eric J Topol; Robert M Califf
Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I.
Circulation 1998;97(8):757-64.
1998: James Gebel; Cathy A Sila; Michael A Sloan; Christopher B Granger; Kenneth W Mahaffey; J Weisenberger; Cynthia L Green; Harvey D White; Joel M Gore; W Douglas Weaver; Robert M Califf; Eric J Topol
Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Stroke; a journal of cerebral circulation 1998;29(3):563-9.
1998: Robert M Califf; A E Abdelmeguid; R E Kuntz; Jeffrey J Popma; C J Davidson; E A Cohen; Neal S Kleiman; Kenneth W Mahaffey; Eric J Topol; C J Pepine; R J Lipicky; Christopher B Granger; Robert A Harrington; Barbara E Tardiff; B S Crenshaw; RP Bauman; B D Zuckerman; B R Chaitman; J A Bittl; Erik Ohman
Myonecrosis after revascularization procedures.
Journal of the American College of Cardiology 1998;31(2):241-51.
1997: Kenneth W Mahaffey; Christopher B Granger; C A Toth; Harvey D White; Amanda L Stebbins; Gabriel I Barbash; A Vahanian; Eric J Topol; Robert M Califf
Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
Journal of the American College of Cardiology 1997;30(7):1606-10.
1996: Kenneth W Mahaffey; Christopher B Granger; R Collins; Christopher M O'Connor; Erik Ohman; S D Bleich; J J Col; Robert M Califf
Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy.
The American journal of cardiology 1996;77(8):551-6.